The FDA has granted accelerated approval to Telisotuzumab vedotin for the treatment of patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-MET protein overexpression. This approval is…
Tag: Treatment Options For Lung Cancer
Heart-Sparing Technique in Lung Cancer Radiotherapy
A new study has been presented at ESTRO 2025 introducing RAPID-RT study. It utilizes an innovative rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. It offers a more inclusive…
Metformin Appears To Fight Lung Cancer But Only In Overweight Patients
Metformin is a common drug prescribed for patients with Type 2 patients to lower their blood sugar. It is a FDA approved drug since 1995 and is used by about 20 million…
FDA Approves New Drug for Lung Cancer
Lung cancer is one of the leading causes behind cancer related deaths. Various studies and research works are going on to help lung cancer patients to get cure from this disease. Time-to-time,…
Tarlatamab for Small Cell Lung Cancer
Lung cancer is the second most form of cancers and remains the leading cause of cancer deaths. A variety of new treatments are helping to bring down the number of deaths from…
Study: Physical Tests Vital in Treating Metastatic Lung Cancer
According to a new study from the researchers in Brazil and the United States, simple physical tests like sitting down, standing up and walking can significantly aid physicians in managing treatments for…
World’s First Lung Cancer Vaccine Trials Launched Across Seven Countries
Lung cancer is the leading cause of cancer deaths all across the world. It accounts for about 1.8m deaths every year. Doctors have begun trailing the world’s first lung cancer vaccine mRNA…
Osimertinib Plus Chemo Approved as Ist-Line Treatment for Patients with Lung Cancer
Lung cancer is the leading cause of cancer deaths among both men and women. It broadly splits into NSCLC and small cell lung cancer. Osimertinib (Tagrisso) in combination with pemetrexed and platinum-containing…